Deka Biosciences

Deka Biosciences

  • Founded: 2018
  • Location: Germantown, MD
  • Employee range: 1 - 10
  • Clinical stage: Clin1
  • Therapy area: Multiple cancers
  • Drug types: ONC, IMM, INF, GI, DRM, RHU
  • Lead product: Diakine-DK210
  • Product link:
  • Funding: $20M A Nov 2021

job board

Short description:

Engineered Therapeutic Proteins

Drug notes:

Also 4 efforts RD multiple cancers; Diakine-DK410 Clin0 sepsis, RD IBD, psoriasis/rheumatoid arthritis; 5 additional programs RD multiple cancers

Long description:

DEKA BioSciences is developing personalized therapeutics for cancer and inflammatory diseases. The body’s natural defense system has the potential to treat various diseases if the right components can be activated. DEKA has created their DiakineTM platform to identify naturally occurring proteins that help regulate the immune system. DiakinesTM comprise a human single-chain variable antibody fragment that links to a combination of cytokines that stimulate the immune system. This modular approach enables DEKA to account for patient differences in cytokine responses. From a single genetic test, DEKA hopes physicians will be able to know what DiakineTM will be the most effective for each patient.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy